Delta TpX

Changing the Prescription for Precision Immunotherapy

About Us

At Delta TpX, we are using optimized human enzymes to target tumor microenvironment regulators and small molecule immune messengers that have been largely unexplored but can be profound drivers of cancer growth and proliferation


Our lead program is focused on the lymphotoxic metabolite 5’-methylthioadenosine (MTA) produced in tumors because of the most common chromosome deletion in cancer at 9p21.3. The biology of this deletion has major clinical implications for patients as a ubiquitous pan-cancer genomic correlate of both the “cold” tumor-immune phenotype and primary resistance to immune checkpoint therapy. Our next program is based on enzymatic targeting of the immunosuppressive metabolite adenosine